Anita H. Chen

Anita H. Chen

Auto-generated profile, based on publicly available information

Anita H. Chen

Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, Florida, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
PDF file
GLGregory Kirk Lewis
Gregory Kirk Lewis
ACAakriti R Carrubba
Aakriti R Carrubba
ASAmanda P. Stanton
Amanda P. Stanton
ECEmily C. Craver
Emily C. Craver
ZLZhuo Li
Zhuo Li
ACAnita H. Chen
Anita H. Chen
Objective: The aim of this study was to highlight the safety of OnabotulinumtoxinA (BTA) injections, with or without concurrent pudendal nerve block, in treating women with myofascial pelvic pain (MFPP). Design: This was a retrospective cohort study. Setting: The review was conducted in a tertiary care academic center. Participants/Materials: We conducted a chart review of patients who were diagnosed with MFPP and treated with BTA with or without pudendal nerve block between January 2010 and February 2022. Methods: BTA was injected transvaginally into the pelvic floor muscle group. The primary outcomes were adverse events after BTA injections, and the secondary outcome was the effect of concomitant pudendal nerve block at the time of BTA injections. Results: The cohort included 182 patients; 103 (56.6%) received BTA injections with pudendal nerve block, and 79 (43.4%) received BTA alone. There were no significant demographic differences between the two groups. Post-treatment complications of BTA administration included worsening of pelvic pain (11.5%), constipation (6.6%), urinary tract infection (2.7%), urinary retention (3.8%), and fecal incontinence (2.7%). No statistical difference was noted in the number of phone calls, patient-initiated electronic messages, emergency room visits, or clinic visits for both groups within 30 days post-treatment. The mean number of total injections was 1.6 in the BTA-only group and 1.7 in the BTA with pudendal block group (p = 0.421). Median time to re-intervention with a second BTA injection was 6.0 months; 5.6 months in the BTA with pudendal block group; and 6.8 months in the BTA-only group, p = 0.46. There were 63 re-intervention events after BTA injections. Limitations: Limitations of our study include the retrospective design making it vulnerable to missing or incomplete data available for review. Conclusion: OnabotulinumtoxinA is beneficial in treating women with MFPP; with a duration of therapeutic effect of approximately 6 months. The use of a concurrent pudendal nerve block did not impact clinical outcomes.

6 May 2022 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
GLGregory K. Lewis
Gregory K. Lewis
SGShilpa N. Gajarawala
Shilpa N. Gajarawala
KRKyle E. Robinson
Kyle E. Robinson
ACAnita H. Chen
Anita H. Chen
MRMatthew W. Robertson
Matthew W. Robertson
Abdominal wall endometriosis with subsequent transformation to clear cell carcinoma is quite rare. The pathogenesis and pattern of this transformation is not well known; hence evaluation and management guidelines are not well established. We highlight a case of clear cell adenocarcinoma arising from the anterior abdominal wall in a previous cesarean section scar treated with excision and the unique addition of Trastuzumab for adjuvant chemotherapy.